(Q37638739)

21 August 2017

1 reference

title

Patented PDE10A inhibitors: novel compounds since 2007. (English)

1 reference

21 August 2017

0 references

Jan Kehler

1

1 reference

PubMed ID

19939189

21 August 2017

John Paul Kilburn

series ordinal

2

1 reference

PubMed ID

19939189

21 August 2017

language of work or name

English

0 references

publication date

1 December 2009

1 reference

Expert Opinion on Therapeutic Patents

21 August 2017

1 reference

21 August 2017

19

1 reference

21 August 2017

12

1 reference

21 August 2017

1715-1725

1 reference

Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A

21 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543770903431050

Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903431050

Isolation and characterization of PDE10A, a novel human 3', 5'-cyclic nucleotide phosphodiesterase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903431050

Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903431050

Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903431050

Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903431050

Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903431050

Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903431050

Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903431050

Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903431050

The role of phosphodiesterases in schizophrenia : therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903431050

Structural insight into substrate specificity of phosphodiesterase 10

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903431050

Structural basis for the activity of drugs that inhibit phosphodiesterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903431050

The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903431050

cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903431050

Crystal structure of the GAF-B domain from human phosphodiesterase 10A complexed with its ligand, cAMP

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903431050

Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903431050

Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903431050

The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903431050

Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903431050

10.1517/13543770903431050

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19939189